Show simple item record

dc.contributor.authorPrentice, RE
dc.contributor.authorTjandra, D
dc.contributor.authorGarg, M
dc.contributor.authorLubel, JS
dc.contributor.authorFourlanos, S
dc.contributor.authorJohnson, D
dc.contributor.authorAl-Ani, A
dc.contributor.authorChristensen, B
dc.date.accessioned2020-12-16T23:52:20Z
dc.date.available2020-12-16T23:52:20Z
dc.date.issued2020-10
dc.identifier.citationPrentice, R. E., Tjandra, D., Garg, M., Lubel, J. S., Fourlanos, S., Johnson, D., Al-Ani, A. & Christensen, B. (2020). Letter: ACE2, IBD and COVID-19-why IBD patients may be at reduced risk of COVID-19.. Aliment Pharmacol Ther, 52 (8), pp.1422-1423. https://doi.org/10.1111/apt.16063.
dc.identifier.issn0269-2813
dc.identifier.urihttp://hdl.handle.net/11343/254607
dc.languageeng
dc.titleLetter: ACE2, IBD and COVID-19-why IBD patients may be at reduced risk of COVID-19.
dc.typeJournal Article
dc.identifier.doi10.1111/apt.16063
melbourne.affiliation.departmentMedical Education
melbourne.affiliation.departmentMedicine and Radiology
melbourne.source.titleAlimentary Pharmacology and Therapeutics
melbourne.source.volume52
melbourne.source.issue8
melbourne.source.pages1422-1423
melbourne.elementsid1466451
melbourne.openaccess.urlhttps://europepmc.org/articles/PMC7537250?pdf=render
melbourne.openaccess.pmchttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537250
melbourne.openaccess.statusPublished version
melbourne.contributor.authorFourlanos, Spiros
melbourne.contributor.authorJohnson, Douglas
melbourne.contributor.authorGarg, Mayur
dc.identifier.eissn1365-2036
melbourne.accessrightsAccess this item via the Open Access location


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record